Business Description
ISIN : US89680M1018
Total Employee Number:
102Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.35 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 5.26 | |||||
Debt-to-EBITDA | -1.58 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -3.8 | |||||
Beneish M-Score | -3.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -69 | |||||
3-Year EBITDA Growth Rate | 82.1 | |||||
3-Year EPS without NRI Growth Rate | 78 | |||||
3-Year FCF Growth Rate | 83.3 | |||||
3-Year Book Growth Rate | 53.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 31.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.86 | |||||
9-Day RSI | 46.71 | |||||
14-Day RSI | 50.34 | |||||
3-1 Month Momentum % | 43.64 | |||||
6-1 Month Momentum % | -5.2 | |||||
12-1 Month Momentum % | -7.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.35 | |||||
Quick Ratio | 4.97 | |||||
Cash Ratio | 4.14 | |||||
Days Inventory | 206.75 | |||||
Days Sales Outstanding | 46.65 | |||||
Days Payable | 190.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.9 | |||||
Shareholder Yield % | -16.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85.79 | |||||
Operating Margin % | -67.68 | |||||
Net Margin % | -62.59 | |||||
EBITDA Margin % | -48.36 | |||||
FCF Margin % | -51.65 | |||||
OCF Margin % | -50.58 | |||||
ROA % | -57.22 | |||||
ROIC % | -590.94 | |||||
3-Year ROIIC % | -41.41 | |||||
ROC (Joel Greenblatt) % | -587.92 | |||||
ROCE % | -58.28 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.46 | |||||
PB Ratio | 46.73 | |||||
Price-to-Tangible-Book | 45.45 | |||||
EV-to-EBIT | -13.24 | |||||
EV-to-Forward-EBIT | -16.63 | |||||
EV-to-EBITDA | -13.58 | |||||
EV-to-Forward-EBITDA | 56.87 | |||||
EV-to-Revenue | 6.57 | |||||
EV-to-Forward-Revenue | 3.9 | |||||
EV-to-FCF | -12.71 | |||||
Price-to-GF-Value | 1.33 | |||||
| Price-to-Net-Current-Asset-Value | 83.33 | |||||
Earnings Yield (Greenblatt) % | -7.55 | |||||
FCF Yield % | -7.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TLSI
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
TriSalus Life Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 45.077 | ||
| EPS (TTM) ($) | -1.3 | ||
| Beta | 0.9189 | ||
| 3-Year Sharpe Ratio | 0.16 | ||
| 3-Year Sortino Ratio | 0.35 | ||
| Volatility % | 74.29 | ||
| 14-Day RSI | 50.34 | ||
| 14-Day ATR ($) | 0.323802 | ||
| 20-Day SMA ($) | 5.233 | ||
| 12-1 Month Momentum % | -7.96 | ||
| 52-Week Range ($) | 2.2 - 7.95 | ||
| Shares Outstanding (Mil) | 61.57 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TriSalus Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TriSalus Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-05 16:30 | In 180 days | ||
| Annual report for 2026 | 2027-03-05 | In 179 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-05 | In 179 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 67 days | ||
| H.C. Wainwright & Company 28th Annual Global Investment Conference | 2026-09-14 17:00 | In 8 days | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-12 08:30 | 5.74 (+3.80%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 4.62 (-2.94%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 4.62 (-2.94%) | ||
| General meeting for 2026 | 2026-05-14 10:00 | 2.67 (-25.83%) |
TriSalus Life Sciences Inc Frequently Asked Questions
Guru Commentaries on NAS:TLSI
TriSalus Life Sciences, Inc. (TLSI) is an oncology-focused medical technology company that specializes in catheters for delivering concentrated chemotherapy doses to liver and pancreatic cancer patients. However, the company posted a significant miss on revenues and lowered guidance during the quarter, citing a Salesforce reorganization and a delayed FDA review of its next-generation device. This led us to reassess our investment thesis, and we became less certain of the company’s total addressable market as cancer treatment trends shift towards radiation over chemotherapy. Consequently, we exited the position in the quarter.
TriSalus Life Sciences, Inc. (TLSI) is an oncology-focused medical technology company that specializes in catheters for delivering concentrated chemotherapy doses to liver and pancreatic cancer patients. However, the company posted a significant miss on revenues and lowered guidance, attributing this to a Salesforce reorganization and a delayed FDA review of its next-generation device. The manager expressed concerns about the company's total addressable market, especially as cancer treatment trends shift towards radiation over chemotherapy, leading to the decision to exit the position.
Press Release
Articles on TriSalus Life Sciences Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
